scholarly journals Pharmacological characteristics and clinical study results of Selexipag (Uptravi® tablets), a selective prostacyclin receptor agonist

2021 ◽  
Vol 156 (3) ◽  
pp. 178-186
Author(s):  
Keiichi Kuwano ◽  
Keiji Kosugi ◽  
Chiaki Fuchikami ◽  
Shunji Funaki
Keyword(s):  
Clinical Study ◽  
Receptor Agonist ◽  
Prostacyclin Receptor ◽  
Study Results

scholarly journals Robust Step Detection from Different Waist-Worn Sensor Positions: Implications for Clinical Studies

2020 ◽  
Vol 4 (1) ◽  
pp. 50-58
Author(s):  
Matthias  Tietsch ◽  
Amir Muaremi ◽  
Ieuan Clay ◽  
Felix Kluge ◽  
Holger Hoefling ◽  
...  
Keyword(s):  
Clinical Study ◽  
Clinical Studies ◽  
Neurological Diseases ◽  
Human Gait ◽  
Robust Solution ◽  
Step Detection ◽  
Study Protocols ◽  
Study Results ◽  
Wide Range ◽  
The Impact

Analyzing human gait with inertial sensors provides valuable insights into a wide range of health impairments, including many musculoskeletal and neurological diseases. A representative and reliable assessment of gait requires continuous monitoring over long periods and ideally takes place in the subjects’ habitual environment (real-world). An inconsistent sensor wearing position can affect gait characterization and influence clinical study results, thus clinical study protocols are typically highly proscriptive, instructing all participants to wear the sensor in a uniform manner. This restrictive approach improves data quality but reduces overall adherence. In this work, we analyze the impact of altering the sensor wearing position around the waist on sensor signal and step detection. We demonstrate that an asymmetrically worn sensor leads to additional odd-harmonic frequency components in the frequency spectrum. We propose a robust solution for step detection based on autocorrelation to overcome sensor position variation (sensitivity = 0.99, precision = 0.99). The proposed solution reduces the impact of inconsistent sensor positioning on gait characterization in clinical studies, thus providing more flexibility to protocol implementation and more freedom to participants to wear the sensor in the position most comfortable to them. This work is a first step towards truly position-agnostic gait assessment in clinical settings.

scholarly journals Disseminating clinical study results to trial participants in Ethiopia: insights and lessons learned

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Tamiru S. Degaga ◽  
Sophie Weston ◽  
Tedla T. Tego ◽  
Dagimawie T. Abate ◽  
Ashenafi Aseffa ◽  
...  
Keyword(s):  
Clinical Study ◽  
Lessons Learned ◽  
Study Results ◽  
Trial Participants

scholarly journals Pharmacological and clinical study results of trastuzumab deruxtecan (T-DXd, ENHERTU®)

2021 ◽  
Vol 156 (1) ◽  
pp. 47-51
Author(s):  
Kaku Saito ◽  
Reina Kaneko ◽  
Takahiro Kamio ◽  
Emi Kamiyama ◽  
Ryo Muto ◽  
...  
Keyword(s):  
Clinical Study ◽  
Study Results

Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension

2020 ◽  
Vol 77 (15) ◽  
pp. 1208-1212
Author(s):  
John J Radosevich ◽  
Audra DeChristopher ◽  
Maykel Irandost ◽  
Jade Fann ◽  
Jeremy Feldman
Keyword(s):  
Receptor Agonist ◽  
Pulmonary Arterial Pressure ◽  
Right Heart Catheterization ◽  
Heart Catheterization ◽  
Target Dose ◽  
Right Heart ◽  
Prostacyclin Receptor ◽  
Rapid Transition ◽  
Pulmonary Arterial ◽  
Mild Headache

Abstract Purpose Selexipag is an oral nonprostanoid IP prostacyclin receptor agonist that is indicated for treatment of pulmonary arterial hypertension (PAH). In patients with continued symptoms of PAH despite maximized oral therapy with selexipag and other oral therapies, a transition to parenteral prostacyclin may be warranted. There is a paucity of data regarding how to safely transition from oral selexipag to parenteral treprostinil. We describe rapid transition from oral selexipag to parenteral treprostinil in this case report. Summary A 65-year-old female with mixed-etiology PAH as result of pulmonary fibrosis related to polymyositis was admitted to the intensive care unit to be transitioned from selexipag to treprostinil due to dyspnea at rest despite therapy with selexipag 1,600 mg twice daily and macitentan 10 mg daily for 3 years. At baseline the patient required oxygen support (4 L/min) at rest to maintain oxygen saturation at or above 90%. Right heart catheterization performed 8 weeks prior to admission revealed severe PAH, with a pulmonary arterial pressure of 73/27 mm Hg and pulmonary vascular resistance of 10 Wood units. On the day of admission the patient was given selexipag 800 µg at 9 am and simultaneously started on intravenous (i.v.) treprostinil at a dose of 2 ng/kg/min. The treprostinil dose was increased by 2 ng/kg/min every 3 hours until a target dose of 22 ng/kg/min was achieved, at which point the patient had experienced dyspnea improvement. She experienced a mild headache and flushing during rapid treprostinil dose escalation. After 30 hours of i.v. treprostinil infusion, the patient was transitioned to subcutaneous treprostinil therapy and discharged. Conclusion In this case the patient was rapidly transitioned from oral selexipag to i.v. and then subcutaneous treprostinil therapy over a 30-hour period, with minimal adverse effects.

Usefulness of a Metal Artifact Reduction Algorithm for Orthopedic Implants in Abdominal CT: Phantom and Clinical Study Results

2015 ◽  
Vol 204 (2) ◽  
pp. 307-317 ◽  
Author(s):  
Seonji Jeong ◽  
Se Hyung Kim ◽  
Eui Jin Hwang ◽  
Cheong-il Shin ◽  
Joon Koo Han ◽  
...  
Keyword(s):  
Clinical Study ◽  
Orthopedic Implants ◽  
Artifact Reduction ◽  
Metal Artifact ◽  
Metal Artifact Reduction ◽  
Reduction Algorithm ◽  
Abdominal Ct ◽  
Study Results
Sign in / Sign up

Export Citation Format

Share Document